Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 3

ash.confex.com

Oral and Poster Abstracts Oral 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: Evolution of Immunotherapeutic Regimens in B-cell Lymphomas Biological, Lymphomas, Non-Hodgkin Lymphoma, Bispecific Antibody Therapy, Diseases, Indolent Lymphoma, Therapies, Lymphoid Malignancies L. Elizabeth Budde1, Laurie H....

  • 123456 Profile photo of Madelyn

    Another phase I/II with monunetuzumab, here as a monotherapy in 90 patients with relapsed refractory follicular lymphoma at 3rd or later line of therapy. ORR was 78.9% and CR rate was 57.8%. CRS was common, occurring in 44.4% of patients, but generally low grade.